BioCentury
ARTICLE | Clinical News

BGB-3111: Phase I started

September 22, 2014 7:00 AM UTC

BeiGene began an open-label, Australian Phase I trial of oral BGB-3111 in patients. The company expects to complete the dose-escalation Phase Ia portion in 2Q15. The Phase Ib portion will enroll disea...